Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Sees Large Decrease in Short Interest

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the recipient of a significant decrease in short interest during the month of August. As of August 14th, there was short interest totaling 223,898 shares, a decrease of 73.3% from the July 30th total of 839,994 shares. Approximately 1.6% of the company’s shares are sold short. Based on an average daily trading volume, of 903,947 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC acquired a new stake in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned approximately 0.72% of Matinas Biopharma at the end of the most recent reporting period. 11.77% of the stock is currently owned by institutional investors and hedge funds.

Matinas Biopharma Price Performance

Shares of MTNB stock remained flat at $0.20 on Friday. The company had a trading volume of 386,117 shares, compared to its average volume of 1,469,259. The business has a 50 day moving average of $0.38 and a two-hundred day moving average of $0.54. Matinas Biopharma has a 52-week low of $0.18 and a 52-week high of $2.14. The company has a market cap of $2.94 million, a PE ratio of -0.17 and a beta of 1.76.

Matinas Biopharma (NYSEAMERICAN:MTNB) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.21) EPS for the quarter.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.